BIOA: BioAge Labs Inc. Stock Price

The daily price chart for BioAge Labs, Inc. (BIOA) reflects the dynamics of a company developing metabolic correction therapies. The business leverages an AI-driven data analysis system focused on longevity, creating high barriers to entry for new players, although stringent FDA oversight prolongs the review process. The current metric stands at 5.56. Despite pressure from industry behemoths, unique biomarkers and the current stage of clinical trials shield BioAge Labs, Inc. (BIOA) from market volatility.

Market Price: BioAge Labs, Inc (BIOA) for 09/27/2024 - 11/14/2026

BioAge Labs - analytical breakdowns and key metrics (BIOA)

- stock quotes and analyst forecast:

Stock Price BioAge Labs, Inc.|BIOA - Price Target Chart

- market capitalization information:

Market Capitalization BioAge Labs|BIOA - Company Buyout Price

- book capitalization information:

Net Assets per Single Share BioAge Labs, Inc.|BIOA - Total Stockholders' Equity|Market Capitalization to Book Value Ratio bioagelabs.com|BIOA - Company Total Assets

- debt and liquidity details:

- company profitability and valuation multiples indicators:

BIOA - Net Income|Projected Future Earnings BioAge Labs, Inc.|BIOA - P/E Multiple|Projected Price to Earnings BioAge|BIOA - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BioAge Labs|BIOA - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) BioAge Labs, Inc.|BIOA - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months bioagelabs.com|BIOA - Net earnings per one share growth for the current year|Earnings growth forecast for next year BioAge Labs, Inc.

- sales and revenue data:

BIOA - Revenue and Sales Volume|Projected Sales Volume BioAge Labs, Inc.|BIOA - Price-to-Revenue Ratio|Price-to-Projected Revenue Ratio BioAge Labs

Fundamental valuation:BioAge Labs, Inc.

Fundamental price analysis minimizes risks by assessing the market consensus regarding asset value and future cash flows. For BioAge Labs, Inc. (BIOA), this indicator reflects investor confidence in the sufficiency of liquidity to fund metabolic research and operating expenses. By analyzing the price trajectory, the user sees a real-time assessment of market expectations, where the share price serves as an integral metric of business valuation.

Analysis of competing companies